Recursion Pharmaceuticals
Series D in 2020
Recursion Pharmaceuticals is a clinical-stage biotechnology company that aims to radically improve patients’ lives by decoding biology through the integration of biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company operates a large-scale drug discovery platform built around Recursion OS, an infrastructure layer and a Map of proprietary biological and chemical data, supported by software tools and machine learning to explore biology beyond human bias and identify new therapeutic opportunities. Its platform includes ReChem for selecting and designing compounds, ReScreen and ReScreenRun for planning and automating large-scale experiments, and ReRun, ReAnalyze, and RePredict for digital signatures, data analysis, and predictive modeling of drug relationships. Founded in 2013, the company is based in Salt Lake City, Utah.
Recursion Pharmaceuticals
Series C in 2019
Recursion Pharmaceuticals is a clinical-stage biotechnology company that aims to radically improve patients’ lives by decoding biology through the integration of biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company operates a large-scale drug discovery platform built around Recursion OS, an infrastructure layer and a Map of proprietary biological and chemical data, supported by software tools and machine learning to explore biology beyond human bias and identify new therapeutic opportunities. Its platform includes ReChem for selecting and designing compounds, ReScreen and ReScreenRun for planning and automating large-scale experiments, and ReRun, ReAnalyze, and RePredict for digital signatures, data analysis, and predictive modeling of drug relationships. Founded in 2013, the company is based in Salt Lake City, Utah.
Recursion Pharmaceuticals
Series B in 2017
Recursion Pharmaceuticals is a clinical-stage biotechnology company that aims to radically improve patients’ lives by decoding biology through the integration of biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company operates a large-scale drug discovery platform built around Recursion OS, an infrastructure layer and a Map of proprietary biological and chemical data, supported by software tools and machine learning to explore biology beyond human bias and identify new therapeutic opportunities. Its platform includes ReChem for selecting and designing compounds, ReScreen and ReScreenRun for planning and automating large-scale experiments, and ReRun, ReAnalyze, and RePredict for digital signatures, data analysis, and predictive modeling of drug relationships. Founded in 2013, the company is based in Salt Lake City, Utah.
Recursion Pharmaceuticals
Series A in 2016
Recursion Pharmaceuticals is a clinical-stage biotechnology company that aims to radically improve patients’ lives by decoding biology through the integration of biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company operates a large-scale drug discovery platform built around Recursion OS, an infrastructure layer and a Map of proprietary biological and chemical data, supported by software tools and machine learning to explore biology beyond human bias and identify new therapeutic opportunities. Its platform includes ReChem for selecting and designing compounds, ReScreen and ReScreenRun for planning and automating large-scale experiments, and ReRun, ReAnalyze, and RePredict for digital signatures, data analysis, and predictive modeling of drug relationships. Founded in 2013, the company is based in Salt Lake City, Utah.
Recursion Pharmaceuticals
Series A in 2016
Recursion Pharmaceuticals is a clinical-stage biotechnology company that aims to radically improve patients’ lives by decoding biology through the integration of biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company operates a large-scale drug discovery platform built around Recursion OS, an infrastructure layer and a Map of proprietary biological and chemical data, supported by software tools and machine learning to explore biology beyond human bias and identify new therapeutic opportunities. Its platform includes ReChem for selecting and designing compounds, ReScreen and ReScreenRun for planning and automating large-scale experiments, and ReRun, ReAnalyze, and RePredict for digital signatures, data analysis, and predictive modeling of drug relationships. Founded in 2013, the company is based in Salt Lake City, Utah.